{
  "ticker": "NUZ",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02964847",
  "id": "02964847",
  "pages": 2,
  "price_sensitive": true,
  "date": "20250702",
  "time": "0849",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250702/pdf/06lcd0t96qs55y.pdf",
  "summary": "- **Global License Agreement with Elanco**: Exclusive rights to Elanco\u2019s IP and data for monepantel (NUZ-001) in neurodegenerative diseases.  \n- **Financial Terms**: Nominal upfront payment; milestone payments of **US$9.75M** (initial) + **US$5.2M** (subsequent) + **US$65M** (sales-based); single-digit royalties on net sales.  \n- **Supply Agreement Expected H2 2025**: Key terms outlined for future GMP-compliant monepantel supply.  \n- **Strategic Impact**: Accelerates regulatory pathway and reduces development costs for NUZ-001 (ALS therapy).  \n\n*Omitted non-material details, director commentary, and operational background.*",
  "usage": {
    "prompt_tokens": 1788,
    "completion_tokens": 159,
    "total_tokens": 1947,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-01T23:04:49.946111"
}